Eli Lilly (NYSE:LLY) announced on Tuesday that its oral weight loss therapy, orforglipron, reached the main goals in a second Phase 3 trial, allowing the company to move forward with global regulatory submissions for the once-daily GLP-1 receptor agonist.
Citing topline data from its Phase 3 ATTAIN-2 trial, the Indiana-based drugmaker said orforglipron accomplished the primary endpoint, generating up to 22.9 lbs (10.5%) of average weight loss over 72 weeks at the highest dose, according to the per-protocol analysis.
“With the completion of ATTAIN-2, Lilly now has the full clinical data package required to initiate global regulatory submissions for orforglipron,” the company added.
Early this month, Lilly (NYSE:LLY) announced that the experimental treatment reached the primary endpoint and all key secondary endpoints in its ATTAIN-1 Phase 3 trial, causing an average weight loss of 12.4% (27.3 lbs) over 72 weeks at the highest dose.
However, Eli Lilly (NYSE:LLY) shares slumped as the readout fell short of Wall Street’s lofty expectations. Novo Nordisk (NVO) and Viking Therapeutics (VKTX), two of LLY’s rivals with obesity pills in their pipelines, traded higher.
This is a developing story. Check back for more updates.